The ADELE clinical trial seeks to improve outcomes for people with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy & radiotherapy.
It is hoped that this study may improve relapse rates in high-risk endometrial cancer by adding Tislelizumab immunotherapy to standard treatment.
TROG Cancer Research
Professor Linda Mileshkin, Peter MacCallum Cancer Centre
Dr Yeh Chen Lee, NHMRC Clinical Trials Centre & Prince of Wales Hospital
The journey to becoming the 200th participant for the
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292